{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:20:48Z","timestamp":1789701648451,"version":"4.0.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chemotherapy-induced thrombocytopenia (CIT) is common, resulting in increased bleeding risk and chemotherapy delays, dose reduction, and treatment discontinuation, which can negatively affect oncologic outcomes. The only agent approved by the US Food and Drug Administration to manage CIT (oprelvekin) was voluntarily withdrawn from the market by the manufacturer, leaving few options for patients. Therefore, patients experiencing CIT present a significant clinical challenge in daily practice. The availability of thrombopoietin receptor agonists has led to formal clinical trials describing efficacy in CIT as well as a rather extensive body of published observational data from off-label use in this setting but no formal regulatory indications for CIT to date. The accumulated data, however, have affected National Comprehensive Cancer Network guidelines, which now recommend consideration of TPO-RA clinical trials as well as off-label use of romiplostim. This review article details the evidence to date for the management of CIT with thrombopoietin receptor agonists (TPO-RAs), discussing the efficacy data, the specific circumstances when treatment is warranted (and when it is generally unnecessary), and safety considerations. Specific recommendations regarding patient selection, initiation, dosing, titration, and discontinuation for TPO-RA therapy in CIT are given, based on published data and expert opinion where evidence is lacking.<\/jats:p>","DOI":"10.1182\/hematology.2022000374","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:10:00Z","timestamp":1670602200000},"page":"286-295","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":28,"title":["Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem"],"prefix":"10.1182","volume":"2022","author":[{"given":"Hanny","family":"Al-Samkari","sequence":"first","affiliation":[{"name":"1 Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA"},{"name":"2 Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"4","key":"2022120916081068800_hem2022000374C1","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"2022120916081068800_hem2022000374C2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11239-017-1478-0","article-title":"Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study","volume":"43","author":"Mantha","year":"2017","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2022120916081068800_hem2022000374C3","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"J Clin Oncol"},{"issue":"31","key":"2022120916081068800_hem2022000374C4","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy- induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2022120916081068800_hem2022000374C5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3324\/haematol.2020.251900","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Al-Samkari","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2022120916081068800_hem2022000374C6","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non- haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol"},{"issue":"5","key":"2022120916081068800_hem2022000374C7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Al-Samkari","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2022120916081068800_hem2022000374C8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00063030-199810020-00006","article-title":"Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia","volume":"10","author":"Wilde","year":"1998","journal-title":"BioDrugs"},{"issue":"5","key":"2022120916081068800_hem2022000374C9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med"},{"issue":"11","key":"2022120916081068800_hem2022000374C10","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdm341","article-title":"Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma","volume":"18","author":"Moskowitz","year":"2007","journal-title":"Ann Oncol"},{"issue":"12","key":"2022120916081068800_hem2022000374C11","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2022120916081068800_hem2022000374C12","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2022120916081068800_hem2022000374C13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.6004\/jnccn.2015.0166","article-title":"Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices","volume":"13","author":"Denduluri","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"2022120916081068800_hem2022000374C14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12885-015-1038-y","article-title":"Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans","volume":"15","author":"Aspinall","year":"2015","journal-title":"BMC Cancer"},{"issue":"3","key":"2022120916081068800_hem2022000374C15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.critrevonc.2014.10.006","article-title":"A review of relative dose intensity and survival in patients with metastatic solid tumors","volume":"93","author":"Havrilesky","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2022120916081068800_hem2022000374C16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2012.12.017","article-title":"Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer","volume":"129","author":"Hanna","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"11","key":"2022120916081068800_hem2022000374C17","first-page":"1558","article-title":"Issues in the management of cancer-related thrombocytopenia","volume":"16","author":"Goodnough","year":"2002","journal-title":"Oncology (Williston Park)"},{"key":"2022120916081068800_hem2022000374C18","doi-asserted-by":"crossref","first-page":"2040620719841735","DOI":"10.1177\/2040620719841735","article-title":"Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia","volume":"10","author":"Al-Samkari","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2022120916081068800_hem2022000374C19","doi-asserted-by":"crossref","first-page":"2040620720912992","DOI":"10.1177\/2040620720912992","article-title":"The role of romiplostim for pediatric patients with immune thrombocytopenia","volume":"11","author":"Al-Samkari","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"16","key":"2022120916081068800_hem2022000374C20","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2022120916081068800_hem2022000374C21","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.gastro.2013.10.012","article-title":"Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy","volume":"146","author":"Afdhal","year":"2014","journal-title":"Gastroenterology"},{"issue":"1","key":"2022120916081068800_hem2022000374C22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.15280","article-title":"Romiplostim for the management of perioperative thrombocytopenia","volume":"182","author":"Al-Samkari","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2022120916081068800_hem2022000374C23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bja.2018.09.010","article-title":"Perioperative thrombocytopenia: evidence, evaluation, and emerging therapies","volume":"122","author":"Nagrebetsky","year":"2019","journal-title":"Br J Anaesth"},{"issue":"13","key":"2022120916081068800_hem2022000374C24","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-021-01575-1","article-title":"Hetrombopag: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"11","key":"2022120916081068800_hem2022000374C25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1358\/dot.2018.54.11.2899441","article-title":"Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease","volume":"54","author":"Al-Samkari","year":"2018","journal-title":"Drugs Today (Barc)"},{"issue":"4","key":"2022120916081068800_hem2022000374C26","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.3324\/haematol.2017.180166","article-title":"The use of romiplostim in treating chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"103","author":"Al-Samkari","year":"2018","journal-title":"Haematologica"},{"issue":"5","key":"2022120916081068800_hem2022000374C27","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-013-2074-2","article-title":"Romiplostim for management of chemotherapy-induced thrombocytopenia","volume":"22","author":"Parameswaran","year":"2014","journal-title":"Support Care Cancer"},{"key":"2022120916081068800_hem2022000374C28","author":"National Comprehensive Cancer Network","year":"2022"},{"issue":"10","key":"2022120916081068800_hem2022000374C29","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2022120916081068800_hem2022000374C30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int J Hematol"},{"issue":"1","key":"2022120916081068800_hem2022000374C31","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study","volume":"4","author":"Winer","year":"2015","journal-title":"Cancer Med"},{"issue":"8","key":"2022120916081068800_hem2022000374C32","doi-asserted-by":"crossref","first-page":"e26473","DOI":"10.1002\/pbc.26473","article-title":"Romiplostim for therapy-related thrombocytopenia in pediatric malignancies","volume":"64","author":"Jacobson","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2022120916081068800_hem2022000374C33","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1097\/MPH.0000000000001187","article-title":"Romiplostim for immune thrombocytopenia in neuroblastoma patients receiving chemotherapy","volume":"41","author":"Fassel","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"2022120916081068800_hem2022000374C34","doi-asserted-by":"crossref","first-page":"e29548","DOI":"10.1002\/pbc.29548","article-title":"Chemotherapy-induced thrombocytopenia in Ewing sarcoma: implications and potential for romiplostim supportive care","volume":"69","author":"Merjaneh","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2022120916081068800_hem2022000374C35","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/ajh.26338","article-title":"Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia","volume":"96","author":"Song","year":"2021","journal-title":"Am J Hematol"},{"issue":"12","key":"2022120916081068800_hem2022000374C36","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/ajh.25275","article-title":"Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia","volume":"93","author":"Al-Samkari","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"2022120916081068800_hem2022000374C37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/bjh.14792","article-title":"Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy","volume":"178","author":"Fenaux","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"2022120916081068800_hem2022000374C38","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/bcp.13717","article-title":"An alternative intermittent eltrombopag dosing protocol for the treatment of chronic immune thrombocytopenia","volume":"84","author":"Al-Samkari","year":"2018","journal-title":"Br J Clin Pharmacol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/286\/2021939\/286alsamkari.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/286\/2021939\/286alsamkari.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:10:20Z","timestamp":1670602220000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/286\/493530\/Thrombopoietin-receptor-agonists-for-chemotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000374","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}